Quest Diagnostics (DGX) PT Raised to $250 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $241.89 -0.57%
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
UBS analyst Kevin Caliendo raised the price target on Quest Diagnostics (NYSE: DGX) to $250.00 (from $245.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Quest Diagnostics (DGX) PT Raised to $262 at Baird
- Honeywell International (HON) PT Lowered to $261 at BMO Capital
- Lockheed Martin (LMT) PT Raised to $692 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
